Last reviewed · How we verify
Glasdegib Oral Tablet
At a glance
| Generic name | Glasdegib Oral Tablet |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia (PHASE2)
- Molecular Profiling of Advanced Soft-tissue Sarcomas (PHASE3)
- A Study Of PF-04449913 In Select Hematologic Malignancies (PHASE1)
- A Study Of PF-04449913 Administered Alone In Select Solid Tumors (PHASE1)
- Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML (PHASE3)
- Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) (PHASE3)
- A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib (PHASE1)
- Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |